Working… Menu
Trial record 1 of 6 for:    xalud
Previous Study | Return to List | Next Study

Safety and Efficacy of XT-150 for Treatment of Neuropathic Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04466410
Recruitment Status : Recruiting
First Posted : July 10, 2020
Last Update Posted : October 25, 2021
Information provided by (Responsible Party):
Xalud Therapeutics, Inc.

Brief Summary:
Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Neuropathic Pain. Intrathecally administered, single injection.

Condition or disease Intervention/treatment Phase
Neuropathic Pain Biological: XT-150 Biological: Placebo Phase 1

Detailed Description:

XT-150 has been safe and well tolerated in clinical studies of intra-articular knee injections for osteoarthritis.

This is the initial study of XT-150 for treatment of neuropathic pain. For this indication XT-150 must be administered by intrathecal injection. Doses used in the osteoarthritis studies will be studied for neuropathic pain.

Upon safety reviews, doses will be increased by cohorts.

The study is placebo controlled and blinded.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Dose escalation by cohort following safety reviews
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Placebo and active drug are identical in appearance. Randomization will be provided to an unblinded pharmacist. Dosing and clinical assessments will be blinded.
Primary Purpose: Treatment
Official Title: A Double Blind, Placebo Controlled, Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Neuropathic Pain
Actual Study Start Date : April 14, 2021
Estimated Primary Completion Date : January 2023
Estimated Study Completion Date : April 2023

Arm Intervention/treatment
Experimental: Low Dose XT-150
Lowest dose of XT-150. Cohort 1 of the study
Biological: XT-150
Single bolus intrathecal injection
Other Name: IL-10 transgene plasmid DNA injected intrathecally

Experimental: Middle dose XT-150
Middle dose of XT-150. Cohort 2 of the study
Biological: XT-150
Single bolus intrathecal injection
Other Name: IL-10 transgene plasmid DNA injected intrathecally

Experimental: High Dose XT-150
Highest dose of XT-150. Cohort 3 of the study
Biological: XT-150
Single bolus intrathecal injection
Other Name: IL-10 transgene plasmid DNA injected intrathecally

Placebo Comparator: Placebo
PBS for injection. 4 of 16 subjects randomly assigned in each experimental drug cohort
Biological: Placebo

Primary Outcome Measures :
  1. Incidence of Treatment-Emergent Adverse Events [ Time Frame: 6 months ]
    Adverse events

  2. Visual Analog Scale of Pain Intensity [ Time Frame: 6 months ]
    Change from Baseline score, 0 to 100 worst pain

Secondary Outcome Measures :
  1. West Haven-Yale Multidimensional Pain Inventory (WHYMPI/MPI) [ Time Frame: 6 months ]
    measures the impact of pain on patients' lives

  2. Multidimensional Pain Scale (MPS) [ Time Frame: 6 months ]
    Changes from baseline in pain

  3. Neuropathic Pain Symptom Inventory (NPSI) [ Time Frame: 6 months ]
    Evaluates the relative component of neuropathic and nociceptive pain symptoms

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Signed Informed Consent Form
  2. Male or female, between 18 and 80 years of age, inclusive
  3. Clinical indication: Lumbar disk disease with no prior lumbar surgery with radicular pain symptoms and/or signs of compressive neuropathy
  4. Inadequate pain relief (visual analog scale of pain intensity [VASPI] score ≥60 mm on a 0-100 mm scale) lasting ≥3 months
  5. Medically stable as determined by the Principal Investigator in consultation with the Sponsor's Medical Monitor, based on pre-study medical history, physical examination, and clinical laboratory tests
  6. In the judgment of the Principal Investigator, acceptable vital signs: blood pressure; resting heart rate; respirations, and oral temperature
  7. Life expectancy >6 months as determined by the Principal Investigator
  8. Female subjects of child-bearing potential, and those <1 year post-menopausal, must be practicing highly effective methods of birth control such as hormonal methods (e.g., combined oral, implantable, injectable, or transdermal contraceptives), double barrier methods (e.g., condoms, sponge, diaphragm, or vaginal ring plus spermicidal jellies or cream), or total abstinence from heterosexual intercourse for a minimum of 1 full menstruation cycle before study drug administration and agree to continue abstinence for 1 full menstruation cycle after the study is completed
  9. Male subjects who are heterosexually active, and not surgically sterile, must agree to use effective contraception for the duration of the study and for 1 month after the study is completed
  10. Stable medical regimen for ≥2 months before participation
  11. Have suitable lumbar anatomy for intrathecal injection as determined by MRI or X-Ray in the last 6 months.
  12. Willing and able to return for the follow-up (FU) visits
  13. Able to read and understand study instructions, and willing and able to comply with all study procedures
  14. Adequately informed of the nature and risks of the study and give written informed consent before receiving any study specific assessments or procedures
  15. Stable use of non-prescription pain therapy, including massage, TENS, physiotherapy osteopathy, chiropractic and acupuncture for 2 months prior and throughout the study period

Exclusion Criteria:

Subjects must NOT meet any of the following exclusion criteria:

  1. Hypersensitivity, allergy, or significant reaction to any ingredient of the study drug
  2. Any spinal deformity preventing intrathecal injection or making intrathecal injection unsafe
  3. Prior history of lumbar surgery, including fusion and microdiscectomy
  4. History of epidural block or facet block or steroid injection in the last 6 months
  5. Current unstable angina, uncontrolled congestive heart failure, or >1+ pitting edema of lower extremities
  6. History of acute myocardial infarction, transient ischemic attack, stroke, or seizure within 3 months of screening visit
  7. Severe chronic obstructive or restrictive pulmonary disease
  8. Current insulin dependent diabetes mellitus
  9. Current autoimmune conditions or documented immunodeficiency
  10. History of immunosuppressive therapy; high-potency systemic steroids in the last 3 months
  11. Current treatment with systemic immunosuppressive (systemic corticosteroid therapy [equivalent to >10mg/day prednisone] or other strong immunosuppressant)
  12. Current or history of central nervous system cancer
  13. Any malignancy (EXCEPTION: localized non-melanoma skin cancers) within 5 years before the screening visit or currently receiving systemic chemotherapy, radiation therapy, or a surgical stabilization procedure
  14. Significant hepatic disease as indicated by clinical laboratory results for the following: ≥3 times the upper limit of normal (ULN) for aspartate aminotransferase, alanine aminotransferase, ≥ 2.5 time ULN alkaline phosphatase, or ≥1.5 times ULN for total bilirubin)
  15. Severe anemia (Grade 3; hemoglobin <8.0 g/dL, <4.9 mmol/L, <80 g/L; transfusion indicated), Grade 1 white cell counts (lymphocytes <LLN - 800/mm3; <LLN - 0.8 x 109 /L, neutrophils <LLN - 1500/mm3; <LLN - 1.5 x 109 /L)
  16. Significant renal disease as indicated by creatinine ≥1.5 times the upper limit of normal or creatinine clearance <80 mL/minute (Cockcroft-Gault formula estimate)
  17. Confirmed positive for human immunodeficiency virus, hepatitis B virus, or hepatitis C virus
  18. Significant psychological conditions; dementia, major depression, or altered mental state that in the opinion of the Investigator will interfere with study participation
  19. Current treatment with systemic antibiotics or antivirals (EXCEPTION: topical treatments)
  20. Current treatment with anticoagulant or antiplatelet medications (EXCEPTION: aspirin and other NSAIDs)
  21. Current use of systemic corticosteroids (equivalent to >10mg/day prednisone)
  22. Known or suspected history of active alcohol or illicit drug abuse within 1 year before the screening visit
  23. Women who are pregnant or nursing
  24. Use of any investigational drug or device within 1 month before randomization or current participation in a trial that included intervention with a drug or device; or currently participating in an investigational drug or device study
  25. Any condition that, in the opinion of the Principal Investigator, could compromise the safety of the subject, the subject's ability to communicate the study staff, or the quality of the data
  26. Presence of an implanted intrathecal infusion system or peripheral neurostimulator
  27. Presence of a generalized pain disorder such as fibromyalgia or complex regional pain syndrome that in the opinion of the PI may impact on evaluation of response to the study drug
  28. Diagnosis of peripheral neuropathy of the lower extremities which in the opinion of the PI, might interfere with the subject's ability to assess the effect of the study drug on the radicular signs and/or symptoms

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04466410

Layout table for location contacts
Contact: Elspeth Hutton, MBBS,PhD,FRACP +61 3 9903 0781‬
Contact: Mahima Kapoor

Layout table for location information
Australia, New South Wales
Genesis Research Services Not yet recruiting
Newcastle, New South Wales, Australia, 2292
Contact: Marc Russo, MD    +61 2 4985 1860   
Principal Investigator: Marc Russo, MD         
Australia, Victoria
Alfred Health Recruiting
Melbourne, Victoria, Australia, 3004
Contact: Jack Germaine    +61 3 9076 2029   
Principal Investigator: Elspeth Hutton, MBBS PhD FRACP         
Sub-Investigator: Mahima Kapoor         
Sponsors and Collaborators
Xalud Therapeutics, Inc.
Layout table for investigator information
Study Director: Stephen Collins, MD/PhD Xalud Therapeutics, Inc.
Layout table for additonal information
Responsible Party: Xalud Therapeutics, Inc. Identifier: NCT04466410    
Other Study ID Numbers: XT-150-1-0102
First Posted: July 10, 2020    Key Record Dates
Last Update Posted: October 25, 2021
Last Verified: October 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Xalud Therapeutics, Inc.:
Plasmid Gene Therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Neurologic Manifestations